Physician profile
Jason A Santiago
NPI 1053845289
$59,808.49
in general payments reported to CMS, 2019-2025
23 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $797 · 2023: $1,369 · 2024: $28K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $10K · Food and Beverage: $4,098 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,191.00 |
| Travel and Lodging | $10,197.99 |
| Food and Beverage | $4,097.57 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $33,633.48 | 2022-2025 | Valtoco |
| Pfizer INC. | $11,455.11 | 2023-2025 | |
| Livanova USA, INC. | $8,442.45 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Ucb Biosciences INC. | $4,500.00 | 2025 | Fintepla |
| Abbvie INC. | $419.00 | 2023 | Qulipta, Duopa, Botox |
| Ucb, INC. | $260.63 | 2022-2023 | Briviact, Fintepla |
| Argenx US, INC. | $179.98 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $138.93 | 2023-2024 | Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $116.75 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $98.96 | 2022-2023 | Ultomiris |
| Biogen, INC. | $95.34 | 2022-2023 | Spinraza |
| Neurocrine Biosciences, INC. | $87.34 | 2022-2023 | Ongentys, Ingrezza |
| Amneal Pharmaceuticals LLC | $75.69 | 2022-2023 | Rytary |
| Eisai INC. | $63.73 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $48.14 | 2022-2023 | Nuplazid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $33.99 | 2023 | |
| Horizon Therapeutics Plc | $33.25 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $23.05 | 2023 | Fycompa |
| Sk Life Science, INC. | $22.16 | 2023 | |
| Axsome Therapeutics, INC. | $22.05 | 2023 | Sunosi |
| Celgene Corporation | $22.04 | 2023 | Zeposia |
| Chiesi USA, INC. | $19.88 | 2022 | |
| Lilly USA, LLC | $16.54 | 2023 | Reyvow, Amyvid, Emgality |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Santiago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.